In this study, we have assessed the clinicopathologic relevance of circulating as well as tumor-specific levels of IGFBP-3 and -4 in melanoma and aimed to define the most clinically relevant test to be integrated in correlative studies of clinical trials targeting IGF. The gene discussed is IGF1; the disease is neoplasm.